

New EMBO Member's Review

IKK α , a critical regulator of epidermal differentiation and a suppressor of skin cancer

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation or the creation of derivative works without specific permission.

Pascal Descargues¹, Alok K Sil² and Michael Karin^{1,*}

¹Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, Cancer Center, School of Medicine, University of California, San Diego, La Jolla, CA, USA and ²Department of Microbiology, University of Calcutta, Kolkata, West Bengal, India

I κ B kinase α (IKK α), one of the two catalytic subunits of the IKK complex involved in nuclear factor κ B (NF- κ B) activation, also functions as a molecular switch that controls epidermal differentiation. This unexpected function requires IKK α nuclear translocation but does not depend on its kinase activity, and is independent of NF- κ B signaling. *Ikk α ^{-/-}* mice present with a hyperproliferative and undifferentiated epidermis characterized by complete absence of a granular layer and *stratum corneum*. *Ikk α* -deficient keratinocytes do not express terminal differentiation markers and continue to proliferate even when subjected to differentiation-inducing stimuli. This antiproliferative function of IKK α is also important for the suppression of squamous cell carcinogenesis. The exact mechanisms by which nuclear IKK α controls keratinocyte proliferation and differentiation remained mysterious for some time. Recent studies, however, have revealed that IKK α is a major cofactor in a TGF β -Smad2/3 signalling pathway that is Smad4 independent. This pathway controls cell cycle withdrawal during keratinocyte terminal differentiation. Although these are not the only functions of nuclear IKK α , this multifunctional protein is a key regulator of keratinocyte and epidermal differentiation and a critical suppressor of skin cancer.

The EMBO Journal (2008) 27, 2639–2647. doi:10.1038/emboj.2008.196; Published online 25 September 2008

Subject Categories: differentiation & death

Keywords: epidermal differentiation; *Ikk α* ; skin cancer; Smads; TGF β

Introduction

The epidermis, the outermost part of the skin, is a stratified and keratinized squamous epithelium mainly composed of keratinocytes, which forms a protective barrier. Epidermal differentiation, which starts in the mouse at embryonic day (E) 12, leads to formation of several distinct cell layers characterized by their ultrastructure, mitotic state and expression of specific molecular markers (Fuchs and Byrne, 1994; Koster and Roop, 2007). The basal layer develops from the surface ectoderm at approximately E9.5 in the mouse. The *p63* gene, which specifies different isoforms of a transcription factor related to tumour suppressor p53, controls basal layer formation and maintenance as well as I κ B kinase α (IKK α) expression (Candi *et al*, 2007; Koster *et al*, 2007). Basal keratinocytes, including epidermal stem cells and transit-amplifying cells, are cuboidal, express cytokeratins (CKs) 5 and 14 and have a high proliferative potential (Koster and Roop, 2007). These cells form the embryonic periderm (M'Boneko and Merker, 1988), which is lost on establishment of the epidermal barrier. At E12 in the mouse, the basal cells give rise to the intermediate cell layer located between the embryonic basal layer and the periderm (Smart, 1970; Weiss and Zelickson, 1975). The intermediate cells divide several times before they withdraw from cell cycle and mature into postmitotic spinous cells (Smart, 1970; Koster and Roop, 2007). By contrast, adult basal keratinocytes directly become spinous cells when terminal differentiation is initiated, without involvement of an intermediate cell type (Koster and Roop, 2007). The spinous layer is characterized by a switch in keratin expression, from CK5 and CK14 to CK1 and CK10 (Fuchs and Green, 1980). Involucrin, a marker of early terminal differentiation is also synthesized in the upper part of this layer. The spinous cells continue their differentiation and maturation to form the granular layer, which is characterized by keratohyalin granules and expression of the late differentiation markers loricrin and filaggrin (Candi *et al*, 2005). Terminal differentiation gives rise to the cornified layer (*stratum corneum*), which consists of extremely flat, keratin-filled and anucleated keratinocytes, called corneocytes, which are mummified within a lipid matrix (Candi *et al*, 2005; Segre, 2006). The *stratum corneum* is primarily responsible for the barrier function of the skin (Elias, 2004; Segre, 2006), which is established around E17.5 in mouse (Hardman *et al*, 1998). Although major progress has been made in understanding the molecular changes that characterize epidermal differentiation, less is known about the signalling

*Corresponding author. Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, Cancer Center, School of Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0723, La Jolla, CA 92093-0723, USA. Tel.: +1 858 534 1361; Fax: +1 858 534 8158; E-mail: karinoffice@ucsd.edu

Received: 9 July 2008; accepted: 3 September 2008; published online: 25 September 2008

pathways that control these events. Here, we provide an overview of the current understanding of the central function of IKK α in the control of epidermal differentiation, homeostasis and tumorigenesis.

Defective epidermal morphogenesis in *Ikk α* -deficient mice

The oligomeric IKK complex is composed of two catalytic subunits, IKK α and IKK β (DiDonato *et al*, 1997; Mercurio *et al*, 1997; Woronicz *et al*, 1997; Zandi *et al*, 1997), and a regulatory subunit named IKK γ or NEMO (nuclear factor κ B (NF- κ B) essential modulator) (Rothwarf *et al*, 1998; Yamaoka *et al*, 1998). This complex is the key mediator of NF- κ B activation in response to proinflammatory and innate immune challenges (Rothwarf *et al*, 1998). Although IKK α and IKK β share considerable sequence identity, it is IKK β that usually serves the more critical function in the activation of classical NF- κ B signalling (Tanaka *et al*, 1999; Li *et al*, 1999b, c). To determine the unique functions of IKK α , several groups have disrupted the *Ikk α* locus in mice and were surprised to find that it has an essential function in epidermal differentiation and morphogenesis (Hu *et al*, 1999; Li *et al*, 1999a; Takeda *et al*, 1999). Newborn *Ikk α* ^{-/-} mice present with multiple morphological defects, including shiny and translucent skin, absence of erupted whiskers, shortened limbs and truncated snout and tail (Figure 1) (Hu *et al*, 1999; Takeda *et al*, 1999; Yoshida *et al*, 2000). These mice develop to term but die shortly after birth, probably as a consequence of a major skin barrier defect that results in severe dehydration.

The *Ikk α* ^{-/-} epidermis is characterized by the presence of basal and suprabasal layers, both in a highly proliferative state, and complete absence of the granular and the cornified layers (Figure 2A) (Hu *et al*, 1999; Takeda *et al*, 1999). At the molecular level, these anomalies are characterized by the expression of CK5 and CK14 as well as proliferating cell markers, such as CK6, PCNA (proliferating cell nuclear antigen) and Ki67 in basal and suprabasal layers (Hu *et al*, 1999; Takeda *et al*, 1999). In contrast, CK1 and CK10 are appropriately expressed in the first suprabasal layers of the *Ikk α* ^{-/-} epidermis (Hu *et al*, 1999; Takeda *et al*, 1999). Involucrin is also synthesized in the upper part of the suprabasal layer of

these mice (Takeda *et al*, 1999), indicating that an early step in the differentiation process still takes place, although late terminal differentiation markers, including loricrin and filaggrin, are not expressed (Hu *et al*, 1999; Takeda *et al*, 1999) (Figure 2B). It was suggested that the highly proliferative suprabasal cells of the *Ikk α* ^{-/-} epidermis, which express CK1 and CK10, are reminiscent of intermediate cells rather than spinous cells (Koster and Roop, 2007). Hence, the most critical function of IKK α may be induction of cell cycle exit needed for converting basal and intermediate keratinocytes to spinous cells. When this step fails, all subsequent differentiation states are aborted (Figure 3).

Nuclear IKK α controls terminal differentiation of keratinocytes

Control of epidermal proliferation and differentiation by IKK α does not involve its protein kinase function and is completely independent from NF- κ B activation (Hu *et al*, 2001). *Ikk α* ^{-/-} keratinocytes do not exhibit a primary defect in NF- κ B activation (Hu *et al*, 1999; Takeda *et al*, 1999). In contrast, *Ikk α* ^{-/-} keratinocytes display higher IKK and NF- κ B activities than wild-type (WT) cells after incubation with either tumour necrosis factor- α or interleukin-1 (Hu *et al*, 2001). The observations that transgenic mice overexpressing a dominant inhibitor of NF- κ B function (I κ B α M) in the epidermis or mice lacking both RelA and c-Rel display epidermal hyperplasia that does not disrupt terminal differentiation and *stratum corneum* formation (Seitz *et al*, 1998; Gugasyan *et al*, 2004; Zhang *et al*, 2004), are consistent with the NF- κ B-independent action of IKK α in the epidermis.

As observed *in vivo*, isolated *Ikk α* ^{-/-} keratinocytes are hyperproliferative and do not respond to differentiation-inducing signals such as confluence or high Ca²⁺ (Hu *et al*, 1999, 2001). *Ikk α* ^{-/-} keratinocytes, however, do differentiate *in vitro* when transduced by an adenovirus expressing a 'kinase-dead' form of IKK α , indicating that the kinase function is dispensable for keratinocyte differentiation (Hu *et al*, 2001). Instead, IKK α needs to enter the nucleus to induce keratinocyte cell cycle arrest and terminal differentiation (Sil *et al*, 2004). Nuclear entry depends on a nuclear localization sequence (NLS) within the IKK α kinase domain, the disruption of which prevents the induction of keratinocyte




Figure 1 Macroscopical presentation of WT and *Ikk α* ^{-/-} mice.




Figure 2 (A) Haematoxylin and eosin staining of skin sections from WT and *Ikkα*^{-/-} mice. (B) Schematic representation of normal and *Ikkα*-deficient epidermis with expression profile of molecular markers of proliferation and differentiation (BL: basal layer; SP: spinous layer; GR: granular layer; SC: stratum corneum; hf: hair follicle; de: dermis; magnification $\times 100$ in (A)).




Figure 3 Schematic representation of epidermal development stages. We propose that the main function of IKK α is to induce cell cycle exit of intermediate keratinocytes when they mature into spinous cells.

differentiation (Sil *et al*, 2004). An NLS is absent from IKK β , which cannot substitute for IKK α in keratinocyte differentiation and growth arrest. IKK α is also nuclear in basal and suprabasal cells of the epidermis (Descargues *et al*, 2008) and

the oral epithelium (Maeda *et al*, 2007), findings that are consistent with the cell culture results.

The function of IKK α in the keratinocyte nucleus is linked to the production of a yet-to-be identified soluble factor or group of factors termed keratinocyte differentiation-inducing factor (kDIF) that can induce the expression of terminal differentiation markers, even in *Ikkα*^{-/-} cells (Hu *et al*, 2001). Consistent with the existence of kDIF, transplantation of *Ikkα*^{-/-} skin onto the back of immunodeficient WT mice allows the *Ikkα*-deficient epidermis to undergo normal differentiation, suggesting that the requirement for IKK α can be bypassed by factors produced by normal skin (Hu *et al*, 2001). These experiments do not exclude the possibility that another important source of kDIF or similarly acting factors are dermal fibroblasts, which are well known to produce factors that control epidermal morphogenesis (Wessells, 1977). In support of this hypothesis, a keratinocyte-specific *Ikkα* disruption results in a less severe epidermal differentiation defect with altered skin barrier function than the total *Ikkα* knockout (Gareus *et al*, 2007). These results were interpreted to suggest that *Ikkα* functions non-autonomously in the dermis to control epidermal differentiation. However, *Ikkα*-deficient keratinocytes from the epidermal-specific knockout mouse still fail to differentiate *in vitro*

(Gareus *et al*, 2007), similar to keratinocytes from total *Ikk α* knockout mice (Hu *et al*, 2001). Collectively, these results indicate that IKK α functions within epidermal keratinocytes and probably in dermal fibroblasts to induce keratinocyte differentiation. As keratinocyte-restricted expression of IKK α , unlike the keratinocyte-specific knockout, does not result in a differentiation defect (Sil *et al*, 2004), it appears that the keratinocyte is the major site of IKK α action with respect to keratinocyte differentiation and epidermal-directed morphogenetic events.

IKK α is a critical component of a Smad4-independent TGF β -Smad2/3 signalling pathway

The most immediate effect of IKK α re-expression in *Ikk α ^{-/-}* keratinocytes is cell cycle withdrawal, which precedes the expression of differentiation markers (Hu *et al*, 2001). Thus, to understand the molecular function of IKK α , we searched for cell cycle-related target genes, the expression of which is IKK α dependent. This search netted several genes encoding negative cell cycle regulators, the expression of which is downregulated in *Ikk α ^{-/-}* keratinocytes and epidermis, including *Mad1* and *Ovol1* (Descargues *et al*, 2008), which encode negative regulators of *Myc*. The *c-Myc* oncogene is thought to influence the balance between keratinocyte proliferation and differentiation, depending on the intensity and timing of its activity (Watt *et al*, 2008). *Mad1* is a basic region/helix-loop-helix/leucine zipper transcriptional regulator that dimerizes with Max to form Mad:Max heterodimers that antagonize the transcriptional function of *Myc*:Max dimers (Ayer *et al*, 1993; Grandori *et al*, 2000). *Mad1^{-/-}* mice, however, are viable, phenotypically normal (Foley *et al*, 1998; Grandori *et al*, 2000) and do not show any epidermal defect. Most likely, other *Mad* genes, including *Mad2*, *Mad3* and *Mad4*, are functionally redundant with *Mad1* and compensate for its loss. Indeed *Mad2* and *Mad3* are also induced in keratinocytes in an IKK α -dependent manner (unpublished data). *Ovol1* is a zinc-finger-containing transcription factor, which, similar to *Mad1*, is also expressed in differentiating suprabasal keratinocytes (Dai *et al*, 1998; Descargues *et al*, 2008). *Ovol1^{-/-}* adult mice present with aberrant hair formation but normal epidermal differentiation (Dai *et al*, 1998). However, the suprabasal epidermis of *Ovol1^{-/-}* embryos shows increased proliferation and *in vitro*, *Ovol1^{-/-}* keratinocytes fail to exit the cell cycle in response to growth-inhibitory signals, such as high Ca²⁺ or TGF β (Nair *et al*, 2006). This defect may be explained in part by abnormal upregulation of *c-Myc*, which is a direct target of *Ovol1* in keratinocytes (Nair *et al*, 2006). Thus, IKK α controls keratinocyte proliferation and cycling through the regulation of several *Myc* antagonists to allow keratinocytes to embark on their differentiation pathway (Figure 4). Interestingly, another TGF β -related mechanism involving Smad3/4 and E2F4/5 transcription factors has been shown earlier to directly inhibit *c-Myc* expression in keratinocytes (Chen *et al*, 2002) (Figure 4). Although this signalling pathway triggers antiproliferative effects of TGF β in keratinocytes, its impact on keratinocyte differentiation is unknown.

Mad1 and *Ovol1* are involved in the inhibition of keratinocyte proliferation induced by TGF β family members




Figure 4 TGF β -related signalling pathway controlling *Myc* activity in keratinocytes. The IKK α -Smad2/3 axis induces *Mad1* and *Ovol 1* expression on TGF β stimulation. These proteins may inhibit the activity and expression of *Myc*, inducing in turn keratinocyte cycle exit and differentiation. Interestingly, a TGF β -Smad3/4 signalling pathway, which is not associated with IKK α , but functions in cooperation with E2F4/5 transcription factors, has also been shown to negatively control *c-Myc* expression in keratinocytes (Chen *et al*, 2002).

(Vastrik *et al*, 1995; Gomis *et al*, 2006), suggesting a link between IKK α and the TGF β signalling pathway. TGF β family members, including TGF β s, activins and BMPs, are cytokines that control cell growth, differentiation and deposition of extracellular matrix through binding to heterodimeric cell surface receptor complexes composed of type I and II subunits, and intracellular Smad transcription factors (Shi and Massague, 2003; Feng and Derynck, 2005; Schmierer and Hill, 2007). The eight mammalian Smad proteins are divided into three distinct groups: receptor-activated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5 and Smad8), a unique common Smad mediator (Co-Smads: Smad4) and inhibitory Smads (i-Smads: Smad6 and Smad7). On ligand binding, the type II receptor activates the type I receptor through its kinase domain, and the type I receptor in turn phosphorylates R-Smads. The activated R-Smads form heterodimeric complexes with Smad4, which accumulate in the nucleus and directly repress or activate specific target genes (Shi and Massague, 2003; Feng and Derynck, 2005; Schmierer and Hill, 2007).

TGF β family members, their receptors and Smad transcription factors are abundantly expressed in epidermal keratinocytes, suggesting homeostatic and regulatory functions (He *et al*, 2001; Li *et al*, 2003). Phosphorylated Smad2 and Smad3 proteins are concentrated in the nuclei of basal and suprabasal keratinocytes, whereas nuclear Smad4 staining is more preminent in basal cells (Descargues *et al*, 2008). Nonetheless, alterations of TGF β signalling in transgenic/knockout mice have often resulted only in minor epidermal defects, thereby obscuring its exact functions in this tissue (Li *et al*, 2003). We recently found that IKK α interacts strongly with Smad3 and weakly with Smad2, but does not bind Smad4 (Descargues *et al*, 2008). IKK α associates with the C-terminal MH2 domain of Smad3 through its kinase domain (unpublished observations). The R-Smad MH2 domain is known to be essential for *trans*-activation, phosphorylation by type I receptors and Smad4 binding (Massague, 2000; Feng and Derynck, 2005). On stimulation by TGF β 1, IKK α and Smad3 form a transcriptional complex that accumulates in the keratinocyte nucleus to directly control the transcription of *Mad1* (Descargues *et al*, 2008). Similar findings were made

for *Ovol1* (unpublished data). In *Ikk α ^{-/-}* keratinocytes stimulated with TGF β 1, Smad3 is no longer recruited to the *Mad1* regulatory region despite its normal association with Smad4. Furthermore, nuclear staining for activated Smad2 and Smad3 is dramatically diminished in the *Ikk α ^{-/-}* epidermis (Descargues *et al*, 2008). Taken together, these results indicate that IKK α is required for nuclear accumulation and chromatin recruitment of phosphorylated Smad2 and Smad3 to IKK α -regulated genes in response to TGF β 1. Interestingly, activin A, an important regulator of epidermal differentiation (Owens *et al*, 2008), is involved in the induction of *Mad1* expression in keratinocytes (Werner *et al*, 2001). As a result, one may speculate that the IKK α -Smad2/3 complex forms and activates anti-Myc genes, including *Mad1*, on activin A signals. As activin A also downregulates the *Id1*, *Id2* and *Id3* genes in keratinocytes (Rotzer *et al*, 2006), it could also be interesting to analyse whether this signalling pathway depends on IKK α . Finally, we found that kDIF functions downstream of the IKK α -Smad2/3 signalling pathway as it can induce differentiation of *Ikk α ^{-/-}* keratinocytes without inducing *Mad1* expression (Figure 5). Exactly how kDIF functions and what it is composed of remain to be determined.

The results mentioned above provided the first clear evidence for a critical function for Smad transcription factors in epidermal differentiation. Although Smad3 deficiency alone does not result in any cutaneous defect (Zhu *et al*, 1998; Datto *et al*, 1999; Yang *et al*, 1999) and the loss of

Smad2 leads to early embryonic lethality (Nomura and Li, 1998; Waldrip *et al*, 1998; Weinstein *et al*, 1998; Heyer *et al*, 1999), loricrin and filaggrin expression is barely detectable in E15.5 embryos lacking both *Smad3* alleles and one *Smad2* allele in their epidermis (Descargues *et al*, 2008). Similarly, siRNA-mediated Smad2 knockdown in Smad3-deficient keratinocytes inhibited the expression of loricrin and filaggrin, as well as *Mad1*, in response to high Ca²⁺ (Descargues *et al*, 2008). These results suggest that Smad2 and Smad3 are functionally redundant. The importance of the TGF β -Smad2/3-*IKK α* axis for proper epidermal differentiation is also underscored by the analysis of transgenic mice in which the i-Smad Smad7 is inducibly expressed in the epidermis, resulting in defective expression of loricrin and filaggrin and failed *stratum corneum* formation (Descargues *et al*, 2008). Consequently, these mutant mice display epidermal hyperplasia due to abnormal proliferation of suprabasal keratinocytes and loss of nuclear IKK α and *Mad1* (Descargues *et al*, 2008).

Surprisingly, this new TGF β response pathway centred around Smad2/3-*IKK α* complex formation is independent of Smad4. Smad4-deficient keratinocytes display normal *Mad1* expression (Descargues *et al*, 2008) and undergo terminal differentiation in response to high Ca²⁺ (unpublished data). These results are consistent with the phenotype of mice with epidermal-specific deletion of *Smad4* (*Smad4^{Δ/Δ}* mice). These mice present with degeneration of hair follicles and dermal cysts that progress to skin tumours in old animals, but do not show any perturbed epidermal differentiation and *stratum corneum* formation (Yang *et al*, 2005; Qiao *et al*, 2006). Furthermore, activated Smad2 and Smad3, as well as IKK α , are normally localized in the nuclei of *Smad4^{Δ/Δ}* keratinocytes, which display normal *Mad1* expression (Descargues *et al*, 2008). Taken together, these results strongly indicate that Smad4 is not required for epidermal differentiation. The Smad4 independence of the TGF β -Smad2/3-*IKK α* signalling pathway is reminiscent of another TGF β signalling operative during erythroid development in which TIF1 γ (also called TRIM33 or ectodermin) replaces Smad4 (He *et al*, 2006). However, TIF1 γ is a RING-type ubiquitin ligase that can target Smad4 to degradation and can therefore function as a negative regulator of Smad4-dependent TGF β signalling (Dupont *et al*, 2005). Hence the exact function of TIF1 γ in TGF β signalling is not fully understood, and it is not known whether it affects the IKK α -dependent pathway.

IKK α and squamous cell carcinoma

IKK α was recently identified as a tumour suppressor in squamous cell carcinoma (SCC) (Liu *et al*, 2006; Maeda *et al*, 2007). SCC is a cancer derived from squamous epithelia of the skin (epidermis), head and neck tissues (mouth, throat, oral and nasal cavities, esophagus) as well as other sites. SCC is the second most common skin cancer in Caucasians with an estimated incidence of 100 000–150 000 new cases per year in the United States (Johnson *et al*, 1992). Sun exposure and immune suppression increase the risk of SCC development and so does tobacco use (Rudolph and Zelac, 2004; Hampton, 2005). SCC of the oral cavity is one of the most prevalent cancers of the head and neck region with a worldwide incidence of 300 000 new cases per year, the




Figure 5 *Mad1* expression is not induced by kDIF-mediated keratinocyte differentiation. Conditioned medium from WT keratinocytes, which contains kDIF as shown earlier (Hu *et al*, 2001), failed to induce *Mad1* expression in *Ikk α ^{-/-}* keratinocytes while leading to keratinocyte differentiation as indicated by filaggrin expression. Only the re-expression of IKK α in *Ikk α ^{-/-}* keratinocytes infected with adenovirus encoding this protein (Ad-IKK α) induces *Mad1* expression.

occurrence of which is linked to tobacco use and betel nut chewing (Silverman, 2001). SCCs of the oral cavity are more aggressive than those developing from the skin, and are associated with a 5-year survival rate of about 50–55% (Silverman, 2001).

Molecular changes in SCCs are characterized by a marked heterogeneity and include activation of oncogenes, such as *RAS*, *MYC*, *EGFR* and *Cyclin D1*, as well inactivation of tumour suppressors, including *p53* and *p16* (Hardisson, 2003). These genetic alterations are thought to influence malignant keratinocyte behaviour and tumour progression, but the precise molecular pathogenesis of SCC is poorly understood. Interestingly, mutations in exon 15 of the *IKK α* locus were described in a few high-grade and poorly differentiated human SCCs of the skin and were shown to be associated with reduced *IKK α* expression (Liu *et al*, 2006). However, it seems that downregulation of *IKK α* due to epigenetic silencing of the *IKK α* locus is a more common occurrence seen in close to 30% of invasive oral SCCs (Maeda *et al*, 2007). It was also reported that overexpression of *IKK α* in the suprabasal compartment, which results in increased epidermal differentiation and reduced keratinocyte proliferation, inhibits chemically induced SCC formation and progression in mice (Liu *et al*, 2006). These results, together with enhanced SCC incidence in *Ikk α ^{+/-}* mice subjected to two-stage skin carcinogenesis and loss of *Ikk α* heterozygosity in the tumours, provide evidence that *IKK α* is a tumour suppressor in the epidermis (Liu *et al*, 2006; Park *et al*, 2007). This function of *IKK α* is probably mediated through the

control of keratinocyte proliferation. The loss of nuclear *IKK α* contributes to malignant conversion of keratinocytes into less differentiated and proliferative carcinoma cells. However, a recent study has suggested that increased *IKK α* may be found in acantholytic SCC (ASCC) (Moreno-Maldonado *et al*, 2008), an histologic variant of SCC showing positive staining for CKs (Rinker *et al*, 2001). Unfortunately, the authors of that study have not carefully analysed whether ASCCs present with loss of nuclear *IKK α* , which would make their results more consistent with other studies mentioned above.

SCC and other carcinoma cells are known to overproduce TGF β 1 to modify their microenvironment through local immunosuppression, extracellular matrix remodelling and neoangiogenesis, and these changes are required for tumour progression and invasiveness (Oft *et al*, 1996, 1998; Siegel and Massague, 2003; Li *et al*, 2005a, 2006). At the same time, carcinoma cells become resistant to TGF β -induced growth arrest (Siegel and Massague, 2003; Li *et al*, 2005a, 2006). Altered *IKK α* function may contribute, at least in part, to acquired resistance to TGF β 1-induced growth arrest.

Conclusions and future directions

Although *IKK α* was first identified as a catalytic subunit of the IKK complex, which mediates NF- κ B activation (DiDonato *et al*, 1997; Mercurio *et al*, 1997; Regnier *et al*, 1997; Zandi *et al*, 1997), it has quickly emerged as a multifunctional protein with several unexpected and surprising activities. In




Figure 6 (A) In the canonical TGF β signalling pathway, ligands signal through type I and II transmembrane protein kinase receptors. After TGF β binding, type II receptor recruits and phosphorylates type I receptor, which in turn activates R-Smads. Phosphorylated R-Smads oligomerize with the co-Smad Smad4 and accumulate in the nucleus where they interact with DNA and transcription factors to regulate the expression of target genes. (B) During epidermal terminal differentiation, TGF β 1 stimulation of keratinocytes induces the formation of a complex between activated Smad2/3 and *IKK α* . This complex accumulates in keratinocyte nuclei independently of the presence of Smad4 and controls the transcriptional activation of *Mad1* and *Ovol1* probably with the cooperation of other transcription factors such as IRF6. The Smad4-independent TGF β -Smad2/3-*IKK α* axis is required for cell cycle exit and induction of terminal differentiation of keratinocytes.

the epidermis, IKK α has turned out to be a critical regulator of keratinocyte proliferation, differentiation and oncogenic transformation, and this function is completely unrelated to its protein kinase activity or NF- κ B signalling. Instead, IKK α functions as a cofactor for Smad2/3 in a Smad4-independent pathway that inhibits keratinocytes proliferation (Descargues *et al*, 2008) (Figure 6). In this capacity, IKK α is required for the induction of a specific subset of TGF β -responsive genes that include the Myc antagonists *Mad1* and *Ovol1*, but is not needed for other well-known TGF β target genes, such as *p21*, *p15* and *p27*, encoding inhibitors of cyclin-dependent kinases (CDKs) (Descargues *et al*, 2008). This is reminiscent of the two different classes of antiproliferative gene responses: Myc repression and inhibition of CDKs, respectively, that are induced during TGF β -mediated cell cycle arrest (Massague *et al*, 2000). It is attractive to speculate that the tumour suppressive function of IKK α is exerted through this pathway as well.

Other proteins may be part of the TGF β -Smad2/3-IKK α signalling pathway, as revealed by two mouse models with functional alterations of 14-3-3 σ (repeated epilation mutant mice) and IRF6, the disruption of which faithfully mimics the phenotype of *Ikk α ^{-/-}* mice (Herron *et al*, 2005; Li *et al*, 2005b; Ingraham *et al*, 2006; Richardson *et al*, 2006). 14-3-3 σ belongs to a family of adaptors that can interact with target proteins in a sequence-specific manner, although its exact function is poorly understood (Mhaweche, 2005). It was reported that IKK α may protect the 14-3-3 σ locus from hypermethylation in keratinocytes by interacting with histone H3 (Zhu *et al*, 2007). In that study, the authors showed that 14-3-3 σ is downregulated in *Ikk α ^{-/-}* keratinocytes, suggesting

that this gene is a downstream target of IKK α (Zhu *et al*, 2007). The human *IRF6* locus is defective in Van der Woude (VWS, OMIM: 119300) and popliteal pterygium (PPS, OMIM: 11500) syndromes, which are characterized by orofacial defects such as cleft lip and palate (Kondo *et al*, 2002). IRF6 belongs to a family of transcription factors that share a highly conserved helix-turn-helix DNA-binding domain and a less conserved protein-binding domain. Interestingly, this protein-binding domain is related to the C-terminal MH2 domain of Smad proteins and has been referred to SMIR (Smad and IRF) domain (Eroshkin and Mushegian, 1999). As DNA binding by Smad transcription factors depends on their association with other DNA-bound transcription factors (Derynck and Zhang, 2003; ten Dijke and Hill, 2004), one can speculate that IRF6 may be a component of the Smad2/3-IKK α transcriptional complex that accumulates in the keratinocyte nucleus to induce the obligatory cell cycle exit that precedes terminal differentiation (Figure 6). In addition, IKK α may also interact with other transcription factors, such as RARs to control epidermal barrier formation (Gareus *et al*, 2007). The identification of other IKK α -interacting proteins and additional IKK α target genes will provide an ever better understanding of how this critical regulator of epidermal proliferation and differentiation carries out its daily work.

Acknowledgements

This study was supported by The International Human Frontier Science Program Organization (to PD), National Institutes of Health grants (to MK) and an American Cancer Society Research Professorship (to MK).

References

- Ayer DE, Kretzner L, Eisenman RN (1993) Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. *Cell* **72**: 211–222
- Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M, Krammer PH, Melino G (2007) TAp63 and DeltaNp63 in cancer and epidermal development. *Cell Cycle* **6**: 274–285
- Candi E, Schmidt R, Melino G (2005) The cornified envelope: a model of cell death in the skin. *Nat Rev Mol Cell Biol* **6**: 328–340
- Chen CR, Kang Y, Siegel PM, Massague J (2002) E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to *c-myc* repression. *Cell* **110**: 19–32
- Dai X, Schonbaum C, Degenstein L, Bai W, Mahowald A, Fuchs E (1998) The ovo gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice. *Genes Dev* **12**: 3452–3463
- Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF (1999) Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. *Mol Cell Biol* **19**: 2495–2504
- Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* **425**: 577–584
- Descargues P, Sil AK, Sano Y, Korchynskiy O, Han G, Owens P, Wang XJ, Karin M (2008) IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation. *Proc Natl Acad Sci USA* **105**: 2487–2492
- DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M (1997) A cytokine-responsive I κ B kinase that activates the transcription factor NF- κ B. *Nature* **388**: 548–554
- Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, Piccolo S (2005) Germ-layer specification and control of cell growth by Ectoderm, a Smad4 ubiquitin ligase. *Cell* **121**: 87–99
- Elias PM (2004) The epidermal permeability barrier: from the early days at Harvard to emerging concepts. *J Invest Dermatol* **122**: xxxvi–xxxix
- Eroshkin A, Mushegian A (1999) Conserved transactivation domain shared by interferon regulatory factors and Smad morphogens. *J Mol Med* **77**: 403–405
- Feng XH, Derynck R (2005) Specificity and versatility in tgf-beta signaling through Smads. *Annu Rev Cell Dev Biol* **21**: 659–693
- Foley KP, McArthur GA, Queva C, Hurlin PJ, Soriano P, Eisenman RN (1998) Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. *EMBO J* **17**: 774–785
- Fuchs E, Byrne C (1994) The epidermis: rising to the surface. *Curr Opin Genet Dev* **4**: 725–736
- Fuchs E, Green H (1980) Changes in keratin gene expression during terminal differentiation of the keratinocyte. *Cell* **19**: 1033–1042
- Gareus R, Huth M, Breiden B, Nenci A, Rosch N, Haase I, Bloch W, Sandhoff K, Pasparakis M (2007) Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. *Nat Cell Biol* **9**: 461–469
- Gomis RR, Alarcon C, He W, Wang Q, Seoane J, Lash A, Massague J (2006) A FoxO-Smad synexpression group in human keratinocytes. *Proc Natl Acad Sci USA* **103**: 12747–12752
- Grandori C, Cowley SM, James LP, Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. *Annu Rev Cell Dev Biol* **16**: 653–699
- Gugasyan R, Voss A, Varigos G, Thomas T, Grumont RJ, Kaur P, Grigoriadis G, Gerondakis S (2004) The transcription factors c-rel and RelA control epidermal development and homeostasis in embryonic and adult skin via distinct mechanisms. *Mol Cell Biol* **24**: 5733–5745
- Hampton T (2005) Skin cancer's ranks rise: immunosuppression to blame. *JAMA* **294**: 1476–1480

- Hardisson D (2003) Molecular pathogenesis of head and neck squamous cell carcinoma. *Eur Arch Otorhinolaryngol* **260**: 502–508
- Hardman MJ, Sisi P, Banbury DN, Byrne C (1998) Patterned acquisition of skin barrier function during development. *Development* **125**: 1541–1552
- He W, Cao T, Smith DA, Myers TE, Wang XJ (2001) Smads mediate signaling of the TGFbeta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis. *Oncogene* **20**: 471–483
- He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J (2006) Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. *Cell* **125**: 929–941
- Herron BJ, Liddell RA, Parker A, Grant S, Kinne J, Fisher JK, Siracusa LD (2005) A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice. *Nat Genet* **37**: 1210–1212
- Heyer J, Escalante-Alcalde D, Lia M, Boettinger E, Edelmann W, Stewart CL, Kucherlapati R (1999) Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. *Proc Natl Acad Sci USA* **96**: 12595–12600
- Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M (1999) Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. *Science* **284**: 316–320
- Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M (2001) IKKalpha controls formation of the epidermis independently of NF-kappaB. *Nature* **410**: 710–714
- Ingraham CR, Kinoshita A, Kondo S, Yang B, Sajjan S, Trout KJ, Malik MI, Dunnwald M, Goudy SL, Lovett M, Murray JC, Schutte BC (2006) Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). *Nat Genet* **38**: 1335–1340
- Johnson TM, Rowe DE, Nelson BR, Swanson NA (1992) Squamous cell carcinoma of the skin (excluding lip and oral mucosa). *J Am Acad Dermatol* **26** (3 Part 2): 467–484
- Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, Howard E, de Lima RL, Daack-Hirsch S, Sander A, McDonald-McGinn DM, Zackai EH, Lammer EJ, Aylsworth AS, Ardinger HH, Lidral AC, Pober BR, Moreno L, Arcos-Burgos M, Valencia C *et al* (2002) Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. *Nat Genet* **32**: 285–289
- Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M, Roop DR (2007) p63 induces key target genes required for epidermal morphogenesis. *Proc Natl Acad Sci USA* **104**: 3255–3260
- Koster MI, Roop DR (2007) Mechanisms regulating epithelial stratification. *Annu Rev Cell Dev Biol* **23**: 93–113
- Li AG, Koster MI, Wang XJ (2003) Roles of TGFbeta signaling in epidermal/appendage development. *Cytokine Growth Factor Rev* **14**: 99–111
- Li AG, Lu SL, Han G, Hoot KE, Wang XJ (2006) Role of TGFbeta in skin inflammation and carcinogenesis. *Mol Carcinog* **45**: 389–396
- Li AG, Lu SL, Han G, Kulesz-Martin M, Wang XJ (2005a) Current view of the role of transforming growth factor beta 1 in skin carcinogenesis. *J Invest Dermatol Symp Proc* **10**: 110–117
- Li Q, Lu Q, Estepa G, Verma IM (2005b) Identification of 14-3-3sigma mutation causing cutaneous abnormality in repeated-epilation mutant mouse. *Proc Natl Acad Sci USA* **102**: 15977–15982
- Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC, Verma IM (1999a) IKK1-deficient mice exhibit abnormal development of skin and skeleton. *Genes Dev* **13**: 1322–1328
- Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM (1999b) Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. *Science* **284**: 321–325
- Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M (1999c) The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. *J Exp Med* **189**: 1839–1845
- Liu B, Park E, Zhu F, Bustos T, Liu J, Shen J, Fischer SM, Hu Y (2006) A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. *Proc Natl Acad Sci USA* **103**: 17202–17207
- M'Boneko V, Merker HJ (1988) Development and morphology of the periderm of mouse embryos (days 9–12 of gestation). *Acta Anat (Basel)* **133**: 325–336
- Maeda G, Chiba T, Kawashiri S, Satoh T, Imai K (2007) Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression. *Clin Cancer Res* **13**: 5041–5047
- Massague J (2000) How cells read TGF-beta signals. *Nat Rev Mol Cell Biol* **1**: 169–178
- Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. *Cell* **103**: 295–309
- Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. *Science* **278**: 860–866
- Mhawech P (2005) 14-3-3 proteins—an update. *Cell Res* **15**: 228–236
- Moreno-Maldonado R, Ramirez A, Navarro M, Fernandez-Acenero MJ, Villanueva C, Page A, Jorcano JL, Bravo A, Llanos Casanova M (2008) IKKalpha enhances human keratinocyte differentiation and determines the histological variant of epidermal squamous cell carcinomas. *Cell Cycle* **7**: 2021–2029
- Nair M, Teng A, Bilanchone V, Agrawal A, Li B, Dai X (2006) Ovol1 regulates the growth arrest of embryonic epidermal progenitor cells and represses *c-myc* transcription. *J Cell Biol* **173**: 253–264
- Nomura M, Li E (1998) Smad2 role in mesoderm formation, left-right patterning and craniofacial development. *Nature* **393**: 786–790
- Oft M, Heider KH, Beug H (1998) TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. *Curr Biol* **8**: 1243–1252
- Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E (1996) TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. *Genes Dev* **10**: 2462–2477
- Owens P, Han G, Li AG, Wang XJ (2008) The role of Smads in skin development. *J Invest Dermatol* **128**: 783–790
- Park E, Zhu F, Liu B, Xia X, Shen J, Bustos T, Fischer SM, Hu Y (2007) Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. *Cancer Res* **67**: 9158–9168
- Qiao W, Li AG, Owens P, Xu X, Wang XJ, Deng CX (2006) Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. *Oncogene* **25**: 207–217
- Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M (1997) Identification and characterization of an IkappaB kinase. *Cell* **90**: 373–383
- Richardson RJ, Dixon J, Malhotra S, Hardman MJ, Knowles L, Boot-Handford RP, Shore P, Whitmarsh A, Dixon MJ (2006) Irf6 is a key determinant of the keratinocyte proliferation–differentiation switch. *Nat Genet* **38**: 1329–1334
- Rinker MH, Fenske NA, Scalf LA, Glass LF (2001) Histologic variants of squamous cell carcinoma of the skin. *Cancer Control* **8**: 354–363
- Rothwarf DM, Zandi E, Natoli G, Karin M (1998) IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. *Nature* **395**: 297–300
- Rotzer D, Krampert M, Sulyok S, Braun S, Stark HJ, Boukamp P, Werner S (2006) Id proteins: novel targets of activin action, which regulate epidermal homeostasis. *Oncogene* **25**: 2070–2081
- Rudolph R, Zelac DE (2004) Squamous cell carcinoma of the skin. *Plast Reconstr Surg* **114**: 82e–94e
- Schmierer B, Hill CS (2007) TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. *Nat Rev Mol Cell Biol* **8**: 970–982
- Segre JA (2006) Epidermal barrier formation and recovery in skin disorders. *J Clin Invest* **116**: 1150–1158
- Seitz CS, Lin Q, Deng H, Khavari PA (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. *Proc Natl Acad Sci USA* **95**: 2307–2312
- Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* **113**: 685–700
- Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. *Nat Rev Cancer* **3**: 807–821
- Sil AK, Maeda S, Sano Y, Roop DR, Karin M (2004) IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. *Nature* **428**: 660–664
- Silverman Jr S. (2001) Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. *J Am Dent Assoc* **132** (Suppl.): 7S–11S

- Smart IH (1970) Variation in the plane of cell cleavage during the process of stratification in the mouse epidermis. *Br J Dermatol* **82**: 276–282
- Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H, Yoshikawa K, Terada N, Akira S (1999) Limb and skin abnormalities in mice lacking IKK α . *Science* **284**: 313–316
- Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV (1999) Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. *Immunity* **10**: 421–429
- ten Dijke P, Hill CS (2004) New insights into TGF-beta-Smad signalling. *Trends Biochem Sci* **29**: 265–273
- Vastrik I, Kaipainen A, Penttila TL, Lymboussakis A, Alitalo R, Parvinen M, Alitalo K (1995) Expression of the mad gene during cell differentiation *in vivo* and its inhibition of cell growth *in vitro*. *J Cell Biol* **128**: 1197–1208
- Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ (1998) Smad2 signaling in extraembryonic tissues determines anterior–posterior polarity of the early mouse embryo. *Cell* **92**: 797–808
- Watt FM, Frye M, Benitah SA (2008) MYC in mammalian epidermis: how can an oncogene stimulate differentiation? *Nat Rev Cancer* **8**: 234–242
- Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX (1998) Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. *Proc Natl Acad Sci USA* **95**: 9378–9383
- Weiss LW, Zelickson AS (1975) Embryology of the epidermis: ultrastructural aspects. III. Maturation and primary appearance of dendritic cells in the mouse with mammalian comparisons. *Acta Derm Venereol* **55**: 431–442
- Werner S, Beer HD, Mauch C, Luscher B, Werner S (2001) The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound repair and psoriasis. *Oncogene* **20**: 7494–7504
- Wessells NK (1977) *Tissue Interaction and Development*. Menlo Park, CA: Benjamin/Cummings
- Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV (1997) IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. *Science* **278**: 866–869
- Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, Israel A (1998) Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. *Cell* **93**: 1231–1240
- Yang L, Mao C, Teng Y, Li W, Zhang J, Cheng X, Li X, Han X, Xia Z, Deng H, Yang X (2005) Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. *Cancer Res* **65**: 8671–8678
- Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. *EMBO J* **18**: 1280–1291
- Yoshida K, Hu Y, Karin M (2000) IkappaB kinase alpha is essential for development of the mammalian cornea and conjunctiva. *Invest Ophthalmol Vis Sci* **41**: 3665–3669
- Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKK α and IKK β , necessary for IkappaB phosphorylation and NF-kappaB activation. *Cell* **91**: 243–252
- Zhang JY, Green CL, Tao S, Khavari PA (2004) NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. *Genes Dev* **18**: 17–22
- Zhu F, Xia X, Liu B, Shen J, Hu Y, Person M, Hu Y (2007) IKK α shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. *Mol Cell* **27**: 214–227
- Zhu Y, Richardson JA, Parada LF, Graff JM (1998) Smad3 mutant mice develop metastatic colorectal cancer. *Cell* **94**: 703–714



The EMBO Journal is published by Nature Publishing Group on behalf of European Molecular Biology Organization. This article is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Licence. [<http://creativecommons.org/licenses/by-nc-nd/3.0>]